tiprankstipranks
Trending News
More News >

Immutep to Present Pivotal Lung Cancer Trial at ELCC 2025

Story Highlights
Immutep to Present Pivotal Lung Cancer Trial at ELCC 2025

Confident Investing Starts Here:

Immutep Ltd ( (AU:IMM) ) has provided an update.

Immutep Limited announced a poster presentation for its pivotal TACTI-004 Phase III trial at the European Lung Cancer Congress 2025. The trial evaluates the combination of Immutep’s eftilagimod alfa with KEYTRUDA and chemotherapy for advanced non-small cell lung cancer. This global trial, enrolling 750 patients across 25 countries, aims to potentially shift treatment paradigms for this cancer type, irrespective of PD-L1 expression, and confirms the promising safety and efficacy of the treatment.

More about Immutep Ltd

Immutep Limited is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. The company is a leader in the field of Lymphocyte Activation Gene-3 (LAG-3) therapeutics, aiming to either stimulate or suppress the immune response. Immutep’s diverse product portfolio is designed to offer innovative treatment options to patients and maximize shareholder value.

YTD Price Performance: -9.09%

Average Trading Volume: 5,000

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: $273.1M

For a thorough assessment of IMM stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App